Investigational drug · Phase 3
DSP
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Atopic Keratoconjunctivitis, Ataxia Telangiectasia.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
18
Any phase or sponsor naming "DSP"
First trial start
2024
Jun 24, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "DSP", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Atopic Keratoconjunctivitis
- Ataxia Telangiectasia
Approved drugs for the same conditions: Neurology · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "DSP" as an intervention, largest first.
Novo Nordisk A/SNovo Nordisk (NVO)
NCT07850765 · 1,260 participants · Start Aug 28, 2026 · Primary completion Aug 31, 2026
Drug: Semaglutide · For: Overweight; Obesity
Sites: Jerusalem, Israel; Mexico City, Mexico; Riyadh, Saudi Arabia · 6 sites in all
- Extended and Controlled Release Liposomal Formulated Dexamethasone for Chronic Knee OA PainPivotal-lookingCompleted
Taiwan Liposome CompanyIndustry
NCT04123561 · 504 participants · Start Nov 26, 2019 · Primary completion Feb 3, 2022
Drug: TLC599; DSP · For: Osteoarthritis of the Knee
Sites: Birmingham, Alabama; Sheffield, Alabama; Phoenix, Arizona · 46 sites in all
- Intra-Erythrocyte Dexamethasone Sodium Phosphate in Ataxia Telangiectasia PatientsPivotal-lookingCompleted
Quince Therapeutics S.p.A.Industry
NCT02770807 · 176 participants · Start Mar 2, 2017 · Primary completion May 13, 2021
Drug: EryDex Low dose DSP; EryDex High dose DSP and 1 more · For: Nervous System Disease; Genetic Syndrome
Sites: Los Angeles, California; Baltimore, Maryland; Cincinnati, Ohio · 22 sites in all
- An Efficacy and Safety Study of DFL24498 in the Treatment of AKCPivotal-lookingRecruiting
Dompé Farmaceutici S.p.AIndustry
NCT07395232 · 153 participants (planned) · Start Dec 1, 2025 · Primary completion Mar 2027
Drug: DFL24498; Vehicle and 1 more · For: Atopic Keratoconjunctivitis
Sites: Jacksonville, Florida; Miami, Florida; Morrow, Georgia · 19 sites in all
- Evaluate the Neurological Effects of EryDex on Subjects With A-TPivotal-lookingCompleted
Quince Therapeutics S.p.A.Industry
NCT06193200 · 105 participants · Start Jun 24, 2024 · Primary completion Dec 17, 2025
Drug: Dexamethasone sodium phosphate · For: Ataxia Telangiectasia
Sites: Los Angeles, California; Baltimore, Maryland; Cincinnati, Ohio · 19 sites in all
Taiwan Liposome CompanyIndustry
NCT03754049 · 102 participants · Start Jan 21, 2019 · Primary completion Nov 7, 2023
Drug: TLC599; DSP · For: Osteoarthritis of the Knee
Sites: Phoenix, Arizona; Miami, Florida; Charleston, South Carolina · 10 sites in all
- Open-Label Extension of EryDex Study IEDAT-04-2022Pivotal-lookingTerminated
Quince Therapeutics S.p.A.Industry
NCT06664853 · 101 participants · Start Dec 11, 2024 · Primary completion Jan 30, 2026
Drug: Dexamethasone sodium phosphate · For: Ataxia Telangiectasia
Sites: Los Angeles, California; Baltimore, Maryland; New Brunswick, New Jersey · 21 sites in all
- Investigator-initiated Clinical Trial (Phase II) of Cancer Vaccine "Dainippon Sumitomo Phama(DSP)-7888" for Acute Myeloid Leukemia Patients.Pivotal-lookingStatus unknown
Osaka UniversityAcademic, hospital or other
NCT04747002 · 100 participants (planned) · Start Jun 12, 2020 · Primary completion Mar 2024
Drug: DSP-7888 · For: Acute Myeloid Leukemia in Remission
Sites: Suita, Japan
Taiwan Liposome CompanyIndustry
NCT03005873 · 76 participants · Start Mar 16, 2017 · Primary completion Jul 4, 2018
Drug: TLC599 LD group; Normal Saline and 1 more · For: Osteoarthritis of the Knee
Sites: Broadmeadow, Australia; Cardiff, Australia; Footscray, Australia · 13 sites in all
Aciont IncAcademic, hospital or other
NCT02309385 · 44 participants · Start Oct 2014 · Primary completion Mar 3, 2017
Drug: 8% Dexamethasone Sodium Phosphate - Visulex; 15% Dexamethasone Sodium Phosphate - Visulex and 1 more · For: Non-Infectious Anterior Uveitis
Sites: Cambridge, Massachusetts; Charlotte, North Carolina; Fargo, North Dakota · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Preparation of Postmortem Human Formalin-Fixed Paraffin-Embedded Frontal Cortex Tissue for Profiling Pyramidal Neurons Via Digital Spatial Profiling.
Stanisavljevic A, Ginsberg SD · Methods Mol Biol 2027
- Deep-DSP2: Cross-Domain Deep Learning Direct MR Signal Prediction for RF Shielding-Free MRI.
Hu J, Zhao Y, Leong ATL, et al. · Magn Reson Med 2027
- A hybrid deep learning and tree-based ensemble approach for forecasting shellfish biotoxin contamination from satellite and in-situ data.
Guegan F, Tavares S, Rodrigues SM, et al. · Harmful Algae 2026
- Dynamics and DSP implementation of a wide-range locally active memristor-coupled Aihara neuron.
Zhang W, He X, Cao Y, et al. · Cogn Neurodyn 2026
- Seasonal dynamics and environmental drivers of particulate algal toxins in coastal planktonic food webs.
Ding X, Yi Z, Li Y, et al. · Mar Pollut Bull 2026
- Can microbial biomass deliver the techno-functional properties required for more sustainable, animal-free foods? A quantitative synthesis linking microbial biomass type, processing, and techno-functionality.
Pereira A, Royen GV, Ganigué R, et al. · Bioresour Technol 2026
Also in development for Atopic Keratoconjunctivitis
- DFL24498Phase 32 trials
Dompé Farmaceutici S.p.A · Dry Eye Disease (DED), Atopic Keratoconjunctivitis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.